Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

KeifeRx, announced that Chief Executive Officer Chris Hoyt will be speaking at two leading investor events during J.P. Morgan Healthcare Conference week. WASHINGTON, DC, UNITED STATES, January 5, 2026 ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

Alumis (ALMS) announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly ...

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...

Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...